Students find coagulation harder than it needs to be, mostly because the cascade is taught as a diagram to memorise rather than as an explanation of what the two tests are doing.
Here is the version that makes the results readable.
Both PT and aPTT measure the same endpoint: how long plasma takes to form a fibrin clot after you start the reaction. What differs is where you start it.
The prothrombin time adds tissue factor and calcium, which starts the cascade at factor VII. So the PT reports on VII, and on the common pathway that follows it — X, V, prothrombin, fibrinogen.
The aPTT adds a contact activator and phospholipid, starting the cascade at XII. So it reports on XII, XI, IX and VIII, and on that same common pathway.
Everything that follows comes from those two starting points.
## Reading the pattern
Prolonged PT, normal aPTT points at factor VII, the only factor that sits in the PT arm alone. In practice this usually means early warfarin effect, early vitamin K deficiency, or early liver disease, because VII has the shortest half-life of the vitamin K dependent factors and falls first.
Normal PT, prolonged aPTT points at the intrinsic arm — VIII, IX, XI, XII. Haemophilia A and B live here. So does heparin. So does a lupus anticoagulant, which prolongs the test without causing bleeding at all, and in fact associates with thrombosis.
Both prolonged means the common pathway, or something affecting everything at once: liver disease, DIC, massive transfusion, severe vitamin K deficiency.
Both normal does not exclude a bleeding disorder. Von Willebrand disease and platelet function defects both sit outside what these tests measure, and factor XIII deficiency prolongs neither.
## The mixing study, in one paragraph
If a test is prolonged, mix the patient's plasma with normal plasma and repeat. If it corrects, the patient was missing something — a factor deficiency. If it does not correct, something in their plasma is interfering — an inhibitor, most commonly a lupus anticoagulant, occasionally a factor-specific antibody.
That single step separates the two broad categories, and it is available to any laboratory with normal plasma and the same analyser.
## What the analyser is doing
Most instruments detect the clot optically, watching light transmission change as fibrin forms. Some use a mechanical method, sensing viscosity change.
The difference matters for one specific reason. Optical detection is affected by what the sample looks like — a heavily lipaemic, icteric or haemolysed plasma can defeat the optical endpoint, and those samples come from exactly the patients whose results are most urgent. Mechanical detection is indifferent to sample colour and turbidity but cannot run chromogenic assays.
Analysers such as the HORIBA Yumizen G400 and the Yumizen G200 cover routine PT, aPTT and fibrinogen with the throughput a hospital laboratory needs. For low volumes or as a backup channel, a single-channel semi-automated instrument like the AGD C-102 does the same four tests without the capital.
## Where results go wrong before the analyser sees them
Citrate tubes must be filled to the mark. The anticoagulant ratio assumes a full tube, and an underfilled one has proportionally too much citrate, which prolongs both PT and aPTT. This produces patients investigated for coagulopathies they do not have, and INRs that alter warfarin doses incorrectly. Reject short tubes rather than reporting them with a comment.
Very high haematocrit reduces plasma volume and does the same thing, which is why markedly polycythaemic patients need adjusted citrate.
And process promptly. Factor activity, particularly factor V and VIII, falls with time and with temperature swings.
## One thing worth remembering about the INR
It exists to standardise PT reporting for patients on warfarin, and it was validated in that population. Applied to liver disease it becomes a measure of hepatic synthetic function rather than a reliable predictor of bleeding — a distinction worth carrying, because a great deal of unnecessary plasma gets transfused on the basis of it.